serum iron, iron-binding capacity, and ferritin levels; and spontaneous recovery from TEC are significantly diagnostic to differentiate these conditions. Inhibitors of heme production have not been found in CHA serum. To determine if inhibitors of heme production occur in TEC or IDA 1 ml human bone marrow cultures were incubated under controled conditions in pairs with and without erythropoietin (EPO) added. FeS9 was added to the cultures for the last 4 hours of incubation and EPO stimulated FeS9 heme production measured. To check for inhibitor activity, 1 p1 of test serum was added to culture pairs. Serum from 8 untransfused TEC patients produced a 2%22% inhibition of FeS9 heme production. In contrast, serum from 2 untransfused CHA and 7 IDA children produced a 43+34% stimulation of ~e " heme production. As recovery occurred, serial serum specimens from 2 TEC patients demonstrated gradual disappearance of inhibitor activity. We conclude that a transient inhibitor of heme production occurs in TEC but not in CHA or IDA. This inhibitor may an imune response and be the mechanism for anemia in TEC. To remove the methodologic flaws of studies claiming that sickle cell trait (Hb AS) impairs physical growth and cognitive development, we prospectively investigated 25 matched pairs (50 subjects) of Black children chosen from a cord blood electrophoresis screening program. For each child with Hb AS, an Hb AA child was matched at birth for sex, birth date, birth weight, gestational age, 5' Apgar score, and socioeconomic status. At ages 3-5 years, each child was evaluated, within one month of his match, by persons "blind" to the hemoglobin genotype. The results are shown below, together with Pa (probability of no difference) and Pg (probability of missing a true AA-AS difference as laree 'as To determine if children with acute lym~hoblastic leukemia (RLL) can mount a primary response to immunization with a new antigen and a secondary response to a known antigen, 39 children with ALL and 51 sibling controls received 2 doses of bivalent split-product influenza vaccine, A Victoria/75, A New Jersey/76 (A/Vic, A/NJ). Before immunization 90% of patients and controls had hemagglutination inhibitinq antibody (HAI) to A/Vic of Z1:8; none showed HA1 antibodies to A/NJ. Four weeks after the first dose 74% of patients and controls showed at least a 4-fold rise in HA1 titer to A/Vic. Only 48% of patients on chemotherapy responded to the first A/NJ immunization compared to 68% of controls and 89% of patients off therapy. Following the second dose, 86% of patients on therapy demonstrated at least a 4-fold rise in titers to both viruses with geometric mean titers of 1:68 to A/Vic and 1:43 to A/NJ. Patients who were off theraoy developed higher HA1 titers than controls. The results demonstrate that patients receiving chemotherapy can produce anti-influenza antibody in response tc immunization with either an old antigen or a new antigen. Responses to the new antiqen in patients on chemotherapy are more sluggish than those of controls but adequate antibody levels are achieved with booster immunization. roup A was born to normal mothers (NM) and suckled on iron decient anemic mothers (AM) until 21 days of age. This group was bdivided into Group A1 fed an iron deficient diet until 49 days age and then given IM iron plus an iron sufficient diet (1x1) d Group A2 given IM iron plus ISD from 21 days. Group B was rn to AM and suckled on NM and thereafter fed an ISD and Grou born to and suckled on NM and thereafter fed on ISD. ups of AM (Group B) had significantly lower body weight, lobin (Hb); brain DNA; spleen weight, DNA, protein and iron ificantly lower body weight, Hb, serum iron, brain weight and ron; liber weight, DNA, RNA, protein and iron; spleen weight, NA, RNA, protein and iron; kidney weight, RNA and iron compared Group C. There was no significant difference between Group B d C. At 49 days, Group A1 had significantly lower body weight, serum iron; brain weight, DNA and iron; liver weight, DNA, , protein and iron; spleen RNA and iron;
, protein and iron compared to Group C.
icant differences were observed in any pa ups. Iron deficiency in rats in utero an eriods results in significant cellular chan iatrics and Laboratory Medicine and Pathology. Minneapolis 55455
Erythrogenesis imperfecta usually begins in infancy and responds to steroid therapy. Because recent observations indicate a widening spectrum, attention to significant variants is important. The K family presents several unusual findings of erythroid hypoplasia syndrome. Well documented episodes of severe anemia due to marrow erythroid hypoplasia (ErHy) has occured in three generations in 3 females and 4 males and is transmitted as an autosomal dominant. In each the anemia presents in the neonatal period. The affected females have had recurrence of severe anemia in each of 6 pregnancies which have spontaneously remitte at parturition. Transfusions are required to maintain hemoglobin above 5 Gm%. The anemia has been normocytic normochromic with M. C.V. in normal range. The innumerable bone marrow examinations have been typical ErHy while in exacerbation but normal during remission. An important difference from other reports is that during the 20 years this family has been followed, therapy with steroids has not been sucessfull. A most remarkable observation has been a reticulocyte response to diathermy treatment noted on several occasions. The female infants remit by 2 years of age whereas the males do not fully respond until 5 years of age. No evidence of thymoma has been seen in this family. All affected individuals have normal growth and development. The pathogenesis of this distinctly different ErHy is currently under investigation. This family provides an important addition to our knowledg, of pure red cell anemia.
